Abstract

The high level of resistance of glioblastoma multiforme (GBM) to currently used chemotherapies and other conventional therapies, its invasive characteristics and the presence of stem-like cells are the major factors that make the treatment of GBM difficult. Recent studies have demonstrated that the homeostasis of energy metabolism, glycolysis and mitochondrial oxidation of glucose are important for GBM cell growth and chemo-resistance. However, it is not clear which specific gene(s) are involved in the homeostasis of energy metabolism and invasiveness of GBM cells. We performed a preliminary analysis of data obtained from Gene Expression Omnibus profiles and determined that malic enzyme 2 (ME2) expression was positively associated with WHO grade in human primary gliomas. Hence, we evaluated the detailed working mechanisms of ME2 in human GBM cell processes, including proliferation, cell cycle, invasion, migration, ROS, and ATP production. Our data demonstrated that ME2 was involved in GBM growth, invasion and migration. ME2 has two cofactors, NAD+ or NADP+, which are used to produce NADH and NADPH for ATP production and ROS clearance, respectively. If the catalytic activity of ME2 is determined to be critical for its roles in GBM growth, invasion and migration, small molecule inhibitors of ME2 may be valuable drugs for GBM therapy. We hope that our current data provides a candidate treatment strategy for GBM.

Highlights

  • The World Health Organization (WHO) classification proposes pathological grading of human gliomas from I to IV, including pilocytic astrocytomas, diffuse astrocytomas, anaplastic astrocytomas and glioblastoma multiforme (GBM; grade IV) [1]

  • The populations of cells in different cell cycle stages were not significantly different in either GBM8401 or LN229 shME2 clone compared to the shLuc control cells; the proportion of cells in subG1 phase was higher in the shME2 clones than in the shLuc control cells (Figure 3C and 3D)

  • We focused on the functions of malic enzyme 2 (ME2) in GBM cells, GBM8401 and LN229, based on the positive correlation between the expression level of ME2 and glioma grade

Read more

Summary

Introduction

The World Health Organization (WHO) classification proposes pathological grading of human gliomas from I to IV, including pilocytic astrocytomas (grade I), diffuse astrocytomas (grade II), anaplastic astrocytomas (grade III) and glioblastoma multiforme (GBM; grade IV) [1]. High-grade (grade III and IV) gliomas have unfavorable prognoses with high lethality due to recurrence after multimodal treatment, including surgical resection and radiation combined with chemotherapy. GBM is the most common and malignant primary brain tumor and has a median survival period of only 12-15 months; survival has not improved since the implementation of the current multimodal treatments [2]. Recent studies have shown that homeostasis of energy metabolism, glycolysis and mitochondrial oxidation of glucose are important for GBM cell growth and chemoresistance [6,7,8,9,10]. There is an urgent need to identify specific gene(s) involved in the homeostasis of energy metabolism and invasiveness of GBM cells

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call